scholarly article | Q13442814 |
P356 | DOI | 10.1097/TP.0000000000000958 |
P698 | PubMed publication ID | 26555944 |
P50 | author | Merville | Q3306691 |
Yvon Lebranchu | Q33292943 | ||
Bruno Moulin | Q42713554 | ||
Marc Hazzan | Q67471891 | ||
Christophe Legendre | Q89834063 | ||
Valérie Châtelet | Q92568235 | ||
Bénédicte Sautenet | Q92692325 | ||
Philippe Lang | Q93102612 | ||
Didier Ducloux | Q96350947 | ||
Benoit Barrou | Q114429034 | ||
Claire Pouteil-Noble | Q114452113 | ||
Emmanuel Morelon | Q116996942 | ||
Olivier Toupance | Q116996945 | ||
Jean-Philippe Rerolle | Q116996946 | ||
Pierre François Westeel | Q116996955 | ||
Raj Purgus | Q116996959 | ||
Johnny Sayegh | Q116996975 | ||
P2093 | author name string | Philippe Zaoui | |
Georges Mourad | |||
Mathias Büchler | |||
Amélie Le Gouge | |||
Gilles Blancho | |||
Caroline Freguin | |||
Christine Mousson | |||
Hedia Boivin | |||
P433 | issue | 2 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | antibody | Q79460 |
rituximab | Q412323 | ||
P304 | page(s) | 391-399 | |
P577 | publication date | 2016-02-01 | |
P1433 | published in | Transplantation | Q15730500 |
P1476 | title | One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial | |
P478 | volume | 100 |
Q90198666 | A potential role of neutrophil extracellular traps (NETs) in kidney acute antibody mediated rejection |
Q39130806 | A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection. |
Q60924756 | ABO-incompatible kidney transplantation as a renal replacement therapy-A single low-volume center experience in Japan |
Q39105369 | Acute antibody-mediated rejection in kidney transplant recipients |
Q38995172 | Anti-thymocyte globulins in kidney transplantation: focus on current indications and long-term immunological side effects. |
Q39366396 | Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies |
Q47773036 | Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression |
Q52401610 | Antibody-mediated rejection: New approaches in prevention and management. |
Q38812914 | Antithymocyte globulins in renal transplantation-from lymphocyte depletion to lymphocyte activation: The doubled-edged sword. |
Q49680578 | Any Progress in the Treatment of Antibody-Mediated Rejection? |
Q86421442 | B cell modulation in transplantation |
Q56967420 | Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: Diagnostic misinterpretation has potential therapeutic implications |
Q39009557 | Chronic allograft injury: Mechanisms and potential treatment targets |
Q90450246 | Circulating B Cells With Memory and Antibody-Secreting Phenotypes Are Detectable in Pediatric Kidney Transplant Recipients Before the Development of Antibody-Mediated Rejection |
Q52586350 | Clinical Utility of Complement-Dependent C3d Assay in Kidney Recipients Presenting with Late Allograft Dysfunction. |
Q55025247 | Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study. |
Q93188012 | Comparing Plasmapheresis plus IVIg with Plasmapheresis plus IVIg plus Rituximab on the Management of Suspicious Antibody-Mediated Acute Rejection in Kidney Transplant Recipients |
Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
Q47286616 | Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection. |
Q52336320 | Engineering therapeutic T cells to suppress alloimmune responses using TCRs, CARs, or BARs. |
Q89746966 | Evaluation and Treatment of Acute Rejection in Kidney Allografts |
Q92429175 | Extracorporeal photopheresis for the treatment of graft rejection in 33 adult kidney transplant recipients |
Q64936489 | Follicular Helper T Cell Derived Exosomes Promote B Cell Proliferation and Differentiation in Antibody-Mediated Rejection after Renal Transplantation. |
Q39708039 | Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion |
Q48656799 | Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation |
Q89367510 | Outcomes of Prolonged Treatment With Intravenous Immunoglobulin Infusions for Acute Antibody-mediated Rejection in Kidney Transplant Recipients |
Q38668319 | Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients |
Q90147875 | Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study |
Q35659332 | Recent advances in renal transplantation: antibody-mediated rejection takes center stage |
Q47157742 | Renal allograft rejection, lymphocyte infiltration, and de novo donor-specific antibodies in a novel model of non-adherence to immunosuppressive therapy |
Q89905301 | Renal transplantation in 2016: Novel approaches to improve recipient and allograft outcomes |
Q52656964 | Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. |
Q40461706 | Rituximab in Combination With Bortezomib, Plasmapheresis, and High-Dose IVIG to Treat Antibody-Mediated Renal Allograft Rejection. |
Q37241071 | Rituximab in the treatment of refractory late acute antibody-mediated rejection: Our initial experience |
Q41041729 | Rituximab use in late antibody-mediated rejection |
Q47737016 | Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. |
Q42102593 | Treatment of Antibody-Mediated Rejection After Kidney Transplantation - 10 Years' Experience With Apheresis at a Single Center. |
Q41967328 | Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step |
Q47920746 | Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial. |
Q58754949 | Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results |
Q90344464 | Trough Level of Mycophenolic Acid Did Not Affect De Novo DSA Development in Kidney Transplantation |
Q38769922 | Use of polyclonal/monoclonal antibody therapies in transplantation |
Q34761349 | What's new in clinical solid organ transplantation by 2013. |
Search more.